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Abstract
Background: Control of malaria in pregnancy remains a public health challenge. Improvements in
its correct diagnosis and the adequacy of protocols to evaluate anti-malarial drug efficacy in
pregnancy, are essential to achieve this goal.
Methods: The presence of Plasmodium falciparum was assessed by real-time (RT) PCR in 284 blood
samples from pregnant women with clinical complaints suggestive of malaria, attending the
maternity clinic of a Mozambican rural hospital. Parasite recrudescences in 33 consecutive paired
episodes during the same pregnancy were identified by msp1 and msp2 genotyping.
Results: Prevalence of parasitaemia by microscopy was 5.3% (15/284) and 23.2% (66/284) by RT-
PCR. Sensitivity of microscopy, compared to RT-PCR detection, was 22.7%. Risk of maternal
anaemia was higher in PCR-positive women than in PCR-negative women (odds ratio [OR] = 1.92,
95% confidence interval [CI] 1.09–3.36). Genotyping confirmed that recrudescence after malaria
treatment occurred in 7 (21%) out of 33 pregnant women with consecutive episodes during the
same pregnancy (time range between recrudescent episodes: 14 to 187 days).
Conclusion: More accurate and sensitive diagnostic indicators of malaria infection in pregnancy
are needed to improve malaria control. Longer follow-up periods than the standard in vivo drug
efficacy protocol should be used to assess anti-malarial drug efficacy in pregnancy.
Background
Pregnant women are at higher risk of Plasmodium falci-
parum infection and disease [1], frequently manifested as
maternal anaemia, pre-term delivery and low birth weight
[2,3]. Infections during pregnancy need to be eliminated
with effective anti-malarials to reduce the burden of dis-
ease in mothers and their children. Current guidelines to
control malaria in pregnancy in sub-Saharan Africa con-
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sist of prompt and effective case management of malaria
illness, combined with prevention of infection and/or dis-
ease through insecticide-treated nets (ITNs) and intermit-
tent preventive treatment (IPTp) [4].
Control of malaria in pregnancy remains a challenge due
to a number of factors. The low specificity of signs and
symptoms [5,6] and the limitations of the techniques to
detect P. falciparum infections impose serious difficulties
in the identification of malaria episodes. Until recently,
malaria diagnosis relied on the microscopic detection of
Plasmodium on Giemsa-stained blood smears. Lately, cir-
culating antigen [7] and polymerase chain reaction
(PCR)-based diagnostic methods [8-12] have been added
as malaria diagnostic tools. In malaria endemic areas, PCR
allows the identification of a high proportion of pregnant
women with P. falciparum parasitaemia levels below the
threshold of microscopy [8-12]. Real-time PCR (RT-PCR),
a more sensitive and specific detection methodology
[13,14], has been shown to be useful in predicting adverse
outcomes of malaria in pregnancy [15,16].
The declining efficacy of classically recommended anti-
malarial drugs due to the increase of anti-malarial-resist-
ant P. falciparum parasites [17], results in multiple treat-
ment failures and prolonged parasitization of the foeto-
placental unit with the subsequent adverse events on
mother and child health. New anti-malarial drug combi-
nations are now being recommended to replace the less
effective ones for the general population. However, there
is limited or non-existent information on the safety and
efficacy of these new drug alternatives in pregnancy. Data
obtained from in vivo studies in children may not be
appropriated for determining anti-malarial treatment effi-
cacy in pregnant women because of differences in host
immunity, as well as pharmacokinetics [18-21]. Critical
analysis of the in vivo standard methods to measure drug
efficacy is essential to correctly monitor drug resistance
and evaluate new anti-malarials to be administered in
pregnancy.
In this study, a PCR-based approach to assess the impact
of sub-microscopic infections on disease manifestation of
pregnant women attending the maternity clinic of a rural
hospital in Mozambique was used. Genetic characteriza-
tion of parasites isolated from consecutive episodes dur-
ing the same pregnancy allowed to determine the extent of
parasite recrudescences after anti-malarial treatment.
Methods
Study area and population
The study was carried out at the Centro de Investigação em
Saúde da Manhiça (CISM) in Manhiça District, southern
Mozambique. Adjacent to the CISM is the Manhiça Dis-
trict Hospital (MDH), a 110 bed health facility, which
provides curative and preventive services. The characteris-
tics of the area have been described in detail elsewhere
[22]. Perennial malaria transmission with some seasonal-
ity is mostly attributed to P. falciparum. Anopheles funestus
is the main vector, and the estimated entomological inoc-
ulation rate for 2002 was 38 infective bites per person per
year [23]. The most recent data on the efficacy of sul-
phadoxine-pyrimethamine (SP) and chloroquine (CQ) in
children in this area showed a combined (early and late)
treatment failure rate of 53% for CQ and 17.3% for SP
[24].
Study design
This study was conducted in the context of a health facil-
ity-based descriptive study that aimed to characterize the
clinical presentation of malaria in Mozambican pregnant
women and to evaluate the adequacy of case management
based on clinical complaints [6]. A round-the-clock mor-
bidity surveillance system was established at the Maternity
Clinic of the Manhica District Hospital (MDH), as a pas-
sive case detection system, for all women attending this
clinic with clinical complaints. Pregnant women attend-
ing the Maternity Clinic between August 2003 and
November 2005, with clinical complaints and who gave
verbal informed consent, were asked for information on
age, parity, gestational age, and signs and symptoms
focused on malaria (axillary temperature ≥ 37.5°C,
referred history of fever in the last 24 hours, pallor, arthro-
myalgias, headache and/or history of convulsions). This
clinical and demographic information was collected onto
a standardized questionnaire. A capillary blood sample
for quantification of P. falciparum parasitaemia and hae-
matocrit, and blood on DNA filter paper (Schleicher &
Schuell number 903™; Dassel, Germany) were collected if
at least one of the pre-defined clinical criteria suggestive of
malaria was met. A random selection of 10% of the filter
papers collected, and all the available filter papers from
women with two consecutive malaria episodes during the
same pregnancy, were analysed by RT-PCR.
Following national guidelines at the time of the study,
women were treated with SP plus CQ in case of non-com-
plicated malaria, except for the first trimester when CQ
alone was given. Oral quinine (Q) for seven days was
given as rescue treatment. Women with complicated
malaria were admitted at the maternity ward, and treated
with parenteral quinine followed by SP. Anaemia was
treated with oral ferrous sulphate and folic acid for one
month. The study protocol was approved by the National
Mozambican Ethics Committee and the Hospital Clinic of
Barcelona Ethics Review Committee.
Laboratory methods
Thick and thin blood films, in duplicate, were stained
with Giemsa and read to determine parasite species andMalaria Journal 2009, 8:9 http://www.malariajournal.com/content/8/1/9
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density of P. falciparum asexual stages per 200 leukocytes,
according to standard, quality-controlled procedures [25].
The haematocrit was measured using a microhaematocrit
centrifuge and read in a Hawksley (Lancing, UK) haemat-
ocrit reader.
Detection of Plasmodium falciparum by real time PCR 
analysis
Parasite DNA was extracted from 50 μl blood on filter
paper by using the ABIPrism 6700 Automated Nucleic
Acid Work Station (Applied Biosystems), according to the
manufacturer's instructions. Negative extraction controls
consisting of water or non-infected erythrocytes were
included in the process. Purified DNA templates were
amplified in an ABI PRISM 7900 HT Real-Time System
(Applied Biosystems) following a previously described
method [13]. Briefly, a 20 μl PCR mixture was performed
using 5 μl of template, 10 μl of 2 × TaqMan® Universal
PCR Master Mix (Applied Biosystems), a 300 nM concen-
tration of each primers specific for 18S ribosomal RNA
gene of P. falciparum, and a 150 nM concentration of
probe labelled with 6-carboxy-fluorescein (FAM) as a
reporter and 6-carboxytetramethylrhodamine (TAMRA)
as a quencher. Amplification and detection were per-
formed under the following conditions: 2 min at 50°C,
10 min at 95°C, and 40 cycles of 15 s at 95°C and 1 min
at 60°C. The results were automatically analysed by the
ABI Prism SDS2.1 software. Each specimen was run in
duplicate. A standard curve was prepared from titrated
samples containing known numbers of ring-infected
erythrocytes diluted in whole blood. The highest dilution
of the curve that gave reproducible results in all the opti-
mization assays was the equivalent to 50 parasites per ml
of blood. The standard curve was run in triplicate for each
test. RT-PCR efficiency was validated by comparing the
slope of the standard curve to the theoretical optimum of
-3.32 which reflects 100% efficient amplification, and was
found to be -3.21 ± 0.13, R2 = 0.99 (n = 5).
Genotyping of P. falciparum isolates
Plasmodium falciparum infections from consecutive
malaria episodes during the same pregnancy were charac-
terized on the basis of the fragment size of the amplified
msp1 (allelic families MAD20, K1 and RO33) and msp2
(allelic families FC27 and 3D7/IC1) loci using a previ-
ously described PCR approach [26]. Each band was con-
sidered an individual strain. Strains were considered the
same if the band had an identical size as determined by
migration in a 2.5% agarose gel. Products from episodes
of the same women were run side-by-side to allow for
direct size comparison. The frequency distribution of the
msp1 and mp2 alleles circulating in the study area was cal-
culated by measuring the proportion of each detected gen-
otype, as defined into 20-base pair ranges, in 60 isolates
from pregnant women [27].
Definitions and statistical methods
A malaria episode was defined as a P. falciparum parasitae-
mia of any density, and presence of any sign and/or symp-
tom suggestive of malaria (presence or history of fever in
the last 24 hours, headache, arthromyalgias, convulsions,
pallor) [6]. Fever was defined as a temperature equal or
higher to 37.5°C, and anaemia as a haematocrit less than
33%. Peripheral blood P. falciparum infections were
grouped into the following categories: a) microscopically
confirmed parasitaemia; b) RT-PCR confirmed parasitae-
mia; c) sub-microscopic infections (negative samples by
microscopic examination which gave a RT-PCR positive
result); d) no infection (negative by microscopy and RT-
PCR). In this study, the duration of a single malaria epi-
sode was estimated as 28 days so as to differentiate
between visits on the same episode and a new episode.
Multiplicity of infection (MOI) was defined as the maxi-
mum number of msp1/msp2-amplicons detected in the
sample. To eliminate the possibility of misclassifying
patients with common msp1 and msp2 variants as treat-
ment failures, recrudescence was only considered when all
strains in the second episode were present in the previous
episode, and no new genotypes were found (i.e., both
msp1 and msp2 amplification products from the second
episode were observed in the previous episode). Infec-
tions in the second episode that consisted on different
strains not present in the previous episode were desig-
nated as new infections. When the second malaria episode
contained strains present in the previous episode but also
new strains, infections were categorized as mixed [28].
Double data entry, validation, and cleaning were done
using Microsoft Visual FoxPro 5.0, and statistical analysis
was performed using STATA.9 (STATA corporation, Col-
lege Station, TX, USA). To evaluate the association
between the presence of signs and symptoms suggestive of
malaria, age, parity, gestational age, number of previous
malaria episodes and season with parasitaemia, univariate
logistic regression models were used. Sensitivity and spe-
cificity of microscopic determination was calculated con-
sidering RT-PCR as the gold standard. The cumulative
probability of two parasites in two independent episodes
being by chance the same for a particular 2-loci genotype
was calculated from the frequencies of msp1 and msp2 gen-
otypes detected in 60 pregnant women [27]. Days
between episodes and multiplicity of infection (MOI)
were compared by t Student's test. Monte Carlo permuta-
tion test with 1,000 random permutations was performed
for each comparison to obtain a more robust estimation
of the p-value [29]. A permutated p-value < 0.05 was con-
sidered statistically significant.Malaria Journal 2009, 8:9 http://www.malariajournal.com/content/8/1/9
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Results
Detection of malaria infection
During the study period (August 2003–November 2005),
3,129 filter papers corresponding to first visits with crite-
ria for blood collection and complete laboratory results
were collected from pregnant women attending the MDH.
Three hundred out of these samples were randomly
selected. Sixteen filter papers were not found. Among the
women from whom the 284 filter papers were available,
70.9% (200/282) were 20–34 years of age, 59.4% (168/
283) were in their second to fourth pregnancies, and
48.2% (137/284) had anaemia.
Of the 284 women, 15 (5.3%) and 66 (23.2%) had
malaria parasitaemia as detected by microscopy and RT-
PCR, respectively. Fifty-one (18.9%) of the 269 women
found to be aparasitaemic by microscopy were positive by
RT-PCR (sub-microscopic infections). Compared with RT-
PCR detection, microscopy showed a sensitivity of 22.7%.
Prevalence of P. falciparum malaria, both by microscopy
and RT-PCR, was equal across age and parity groups
(Table 1 and Table 2). Prevalence of sub-microscopic
infections (n = 51) was not statistically different across
maternal age (p = 1.00), gestational age (p = 1.00) and
gravidity group (p = 0.68). Infections detected by RT-PCR
were more prevalent among women in the third trimester
of pregnancy than among those in the first and second tri-
mester (Table 2), although estimates were not statistically
significant (p = 0.082). This trend was not found in infec-
tions detected by microscopy (Table 1).
Malaria infection and clinical presentation
There was no evidence of an association between signs or
symptoms suggestive of malaria and the presence of
microscopically detected peripheral malaria (Table 1).
Risk of maternal anaemia was higher in women with RT-
PCR detected parasitaemina than in women with a nega-
tive RT-PCR result (Table 2, OR = 1.92, 95% CI 1.09–3.36,
p = 0.026). Women with sub-microscopic infections also
had a statistically significant higher risk of anaemia com-
pared with women with negative microscopy and RT-PCR
test (OR = 2.80, 95% CI 1.46–5.38, p = 0.002). No other
malaria sign or symptom was found to be associated with
PCR-detected or sub-microscopic infections.
Table 1: Association between parasitaemia, as detected by microscopy, and mother age, pregnancy status and signs/symptoms of 
malaria.
Microscopy
negative
n = 269
positive
n = 15
Variable n % n % OR 95% CI p-value*
Age** <20 y 50 19 4 27 1 0.606
20–34 y 190 71 10 67 0.66 (0.20; 2.19)
>= 35 y 27 10 1 7 0.46 (0.05; 4.35)
Gestational age (weeks) 1–12 74 28 3 20 1 0.670
13 – 24 68 25 3 20 1.09 (0.21; 5.58)
> 24 127 47 9 60 1.75 (0.46; 6.66)
Parity*** 0 32 12 0 0 - 0.292
1–3 156 58 12 80 1
>= 4 80 30 3 20 0.49 (0.13; 1.78)
Season Dry 132 49 11 73 1 0.105
Wet 137 51 4 27 0.35 (0.11; 1.13)
Fever No 248 92 13 87 1 0.481
Yes 21 8 2 13 1.82 (0.38; 8.59)
Fever/history of fever*** No 107 40 4 27 1 0.264
Yes 161 60 11 73 1.83 (0.57; 5.89)
Arthromyalgia No 63 23 3 20 1 0.767
Yes 206 77 12 80 1.22 (0.33; 4.47)
Headache No 27 10 4 27 1 0.089
Yes 242 90 11 73 0.31 (0.09; 1.03)
Pallor No 255 95 14 93 1 1.000
Yes 14 5 1 7 1.3 (0.16; 10.61)
Anemia No 137 51 10 67 1 0.288
Yes 132 49 5 33 0.52 (0.17; 1.56)
*, Univariate logistic regression model; **, Two data missing; ***, One data missing; OR, Odds ratio; CI, Confidence interval.Malaria Journal 2009, 8:9 http://www.malariajournal.com/content/8/1/9
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Malaria recrudescence in pregnancy
Eleven msp1 and 20 msp2 genotypes were found in 60
pregnant women, with allelic frequencies ranging from
0.008 to 0.18 (Figure 1). Four msp1 and 3 msp2 variants
were present at frequencies higher than 10%. The cumula-
tive probability of two independent strains being by
chance the same for msp1 and msp2 in two different epi-
sodes was 0.99%. Given this low probability of repeated
occurrence by chance of a particular two-loci genotype in
the same patient, coincidence of both msp1 and msp2 in
consecutive episodes was considered evidence of the same
parasite.
Sixty-six filter papers were analysed from 33 women with
two consecutive malaria episodes during the same preg-
nancy (Table 3). Recrudescent infections (isolates sharing
the same msp1 and msp2 genotypes with no evidence of
new infections) occurred in 7 (21.2%) of the 33 women.
In 22 (66.7%) of the women, the second episode con-
sisted of P. falciparum isolates with msp1 and msp2 geno-
types not present in the previous episodes (new
infections). Mixed infections (both recrudescent and new
strains present) were present in 4 (12.1%) of the women.
Mean duration of the interval between consecutive epi-
sodes was similar in recrudescent (58 days, SD 57.7, range
14–187) and new infections (61.2 days, SD 30, range 20–
129) (p = 0.84). No statistical difference was found in the
mean multiplicity of infection (MOI) from first (1.95, SD
0.89) and second episodes (1.58, SD 0.75) (p = 0.33), and
from recrudescent (1.71, SD 0.48) and new infections
(1.76, SD 0.81) (p = 0.82).
Discussion
This study described the prevalence of P. falciparum infec-
tion detected by real time PCR among Mozambican preg-
nant women attending a rural maternity clinic with
clinical complaints suggestive of malaria. These results
showed that microscopically detectable P. falciparum par-
asitaemia in peripheral blood is a rather poor indicator of
the actual presence of infection in pregnancy, as suggested
by the low sensitivity of microscopy as compared to RT-
PCR (22.7%) and the high prevalence of sub-microscopi-
cally infected women (18.9%). In other settings, sub-pat-
ent malaria infections have been found in up to 55% of
the pregnant women [8-12]. This suggests the existence of
a level of host immunity able to restrict parasites to low,
Table 2: Association between parasitaemia, as detected by RT-PCR, and mother age, pregnancy status and signs/symptoms of 
malaria.
PCR
negative
n = 218
positive
n = 66
Variable n % n % OR 95% CI p-value*
Age** <20 y 38 18 16 24 1 0.480
20–34 y 156 72 44 67 0.67 (0.34; 1.31)
>= 35 y 22 10 6 9 0.65 (0.22; 1.90)
Gestational age (weeks) 1–12 64 29 13 20 1 0.082
13 – 24 58 27 13 20 1.10 (0.47; 2.57)
> 24 96 44 40 61 2.05 (1.02; 4.14)
Parity*** 0 28 13 4 6 1 0.094
1–3 122 56 46 70 2.64 (0.88; 7.94)
>= 4 67 31 16 24 1.67 (0.51; 5.45)
Season Dry 108 50 35 53 1 0.684
Wet 110 50 31 47 0.87 (0.50; 1.51)
Fever No 200 92 61 92 1 1.000
Yes 18 8 5 8 0.91 (0.32; 2.55)
Fever/history of fever*** No 84 39 27 41 1 0.772
Yes 133 61 39 59 0.91 (0.52; 1.60)
Arthromyalgia No 55 25 11 17 1 0.176
Yes 163 75 55 83 1.69 (0.82; 3.45)
Headache No 24 11 7 11 1 1.000
Yes 194 89 59 89 1.04 (0.43; 2.54)
Pallor No 205 94 64 97 1 0.568
Yes 13 6 2 3 0.49 (0.11; 2.24)
Anemia No 121 56 26 39 1 0.026
Yes 97 44 40 61 1.92 (1.09; 3.36)
*, Univariate logistic regression model; **, Two data missing; ***, One data missing; OR, Odds ratio; CI, Confidence interval.Malaria Journal 2009, 8:9 http://www.malariajournal.com/content/8/1/9
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microscopically undetectable densities. Alternatively,
these low-density infections may represent recently
acquired infections which would reach microscopical lev-
els if infection is not treated. Carriage of sub-microscopic
infections has been shown to be common also in non-
pregnant adults [30,31]. However, the occurrence of
microscopically undetected infections are likely to be
more clinically relevant during pregnancy, since malaria
parasitaemia of any density may have a harmful effect on
the pregnant women and her developing foetus
[16,32,33].
In this study, the majority of women presenting clinical
complaints suggestive of malaria were not infected with P.
Prevalence of msp1 and msp2 size variants (in base pairs) in P. falciparum parasite population from Manhiça Figure 1
Prevalence of msp1 and msp2 size variants (in base pairs) in P. falciparum parasite population from Manhiça.
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falciparum, as detected by microscopy (94.7%) and even
by RT-PCR (76.8%). Thus, in this context, presumptive
malaria treatment would lead to unnecessary exposure to
anti-malarial drugs in the majority of pregnant women
presenting with "malaria-like" clinical complaints [6]. On
the other hand, treatment based on microscopically con-
firmed malaria episodes only, might lead to under-treat-
ment because of the significant proportion of infections
bellow the detection threshold of microscopy. The ability
of RT-PCR to detect this additional population of women
at risk for malaria infection that were otherwise micro-
scopically negative would contribute effectively to a better
management of malaria in pregnancy. However, PCR-
based methods require costly reagents and instrumenta-
tion that are not widely available in developing countries.
Rapid tests that detect parasite-specific antigens [7] may
overcome the problem of inadequate diagnosis and treat-
ment. In addition, a more sensitive definition of clinical
malaria in pregnancy should also be evaluated. Other
symptoms and signs could be considered, since those fre-
quently used to define a malaria episode are poor indica-
tors of P. falciparum infection both in pregnant women [6]
and non-pregnant adults [31].
Table 3: Malaria genotypes and multiplicity of infection detected in 33 consecutive paired episodes during the same pregnancy.
msp1/msp2 genotypes
MOI Same in Different in
Infection Episode 1 Episode 2 both episodes episode 2 Tx Days
New
21 0 1 C Q 2 0
11 0 1 C Q 2 5
2 1 0 1 CQ+SP 31
13 0 3 C Q 3 2
2 2 0 2 CQ+SP 35
3 1 0 1 CQ+SP 41
34 0 4 C Q 4 7
1 2 0 2 CQ+SP 47
21 0 1 Q + S P 4 9
21 0 1 C Q 5 0
22 0 2 Q + S P 5 2
42 0 2 C Q 5 5
1 1 0 1 CQ+SP 56
11 0 1 C Q 5 9
2 1 0 1 CQ+SP 64
1 2 0 2 CQ+SP 72
2 1 0 1 CQ+SP 77
1 2 0 2 CQ+SP 81
4 2 0 2 CQ+SP 93
22 0 2 C Q + S P 1 1 6
22 0 2 C Q + S P 1 1 7
21 0 1 C Q 1 2 9
Recrudescent
11 1 0 C Q 1 4
32 2 0 C Q 3 9
2 2 2 0 CQ+SP 41
3 2 2 0 CQ+SP 41
1 1 1 0 CQ+SP 42
22 2 0 C Q 4 2
32 2 0 Q 1 8 7
Mixed
12 1 1 Q 2 9
3 2 1 1 CQ+SP 38
33 1 2 C Q 9 8
33 1 2 C Q 1 2 2
MOI, Multiplicity of infection; Tx, anti-malarial used to treat episode 1; Days, Days between epidodes; Q, Quinine; CQ, Chloroquine; SP, 
Sulphadoxine-Pyrimethamine.Malaria Journal 2009, 8:9 http://www.malariajournal.com/content/8/1/9
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In this study, anaemia was the only symptom associated
with parasitaemia as detected by RT-PCR. This association
was not found for microscopical parasitaemia in this sub-
set of samples, maybe due to limitations of the sample
size. Women with sub-microscopic infections were also at
higher risk of anaemia compared with women with nega-
tive microscopy and RT-PCR test, suggesting a role of low-
density infections in the aetiology of maternal anaemia. A
similar association has been found in some studies
[31,34], but not in others [8,10,12,35], may be due to dif-
ferences in the sensitivity of the molecular technique
used. The results of this study suggest that low-density
asymptomatic infections may significantly increase the
risk of becoming anaemic. Alternatively, anaemia may be
a consequence of recent high density infections controlled
at the time of examination.
PCR-confirmed recrudescences were found in 21% of the
women experiencing two successive episodes during the
same pregnancy. The rate of recrudescences found in this
study raises important questions for drug efficacy in preg-
nancy. First, it suggests that the efficacy of anti-malarial
drugs during pregnancy may be reduced. This can be due
to inadequate drug levels, limited clearing capacity of pla-
cental parasites, or to immunosuppresion and physiolog-
ical changes during pregnancy which are likely to alter the
pharmacokinetics of most anti-malarials [18-21,36]. Sec-
ondly, these results show that recrudescences of P. falci-
parum parasites during pregnancy can occur as late as 187
days. In other studies, reappearance of parasites has been
shown to occur 35, 49, 85 and 119 days after treatment
[37,38]. In Thailand, recrudescence was detected up to 62
days post-treatment in non pregnant individuals and up
to 121 days in pregnant women [27]. Thus, the 28 days
standard in vivo test [39] may not be adequate to assess
the efficacy of anti-malarial drugs in pregnant women,
since it would not detect recrudescences that occur much
later. Various alternative assessment times have been used
to define treatment failures in anti-malarial drug efficacy
studies, ranging from 42 days [40-42] to 63 days [37,38]
after treatment. This study suggests that even longer fol-
low-up may be needed during pregnancy to capture all
treatment failures. It is essential that these studies include
molecular genotyping to distinguish recrudescences from
reinfections.
Conclusion
These results point out two important issues for malaria
control during pregnancy; on the one hand, the need to
apply more accurate and sensitive measures to detect
malaria infections in pregnancy. On the other hand, it
might be necessary to extend the follow-up period for in
vivo tests to correctly identify anti-malarial drug failures
during pregnancy. Appropriate, standardized genotyping
methods should be applied to unequivocally identify
recrudescent parasites. This is essential to optimize the
drug regimens needed to eliminate the plasmodial bio-
mass in pregnant women, and to correctly measure the
efficacy of the existing and new anti-malarials to be used
in pregnancy.
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